Comparison of Six Dilute Russell Viper Venom Time Lupus Anticoagulant Screen/Confirm Assay Kits

Abstract

Background The normalized dilute Russell viper venom time (DRVVT) ratio provides a robust assay methodology for lupus anticoagulant (LA) detection.

Objectives We evaluated six normalized DRVVT LA screen and confirm systems for inter-method consistency. Reagents were purchased from Diagnostica Stago, Inc. (Parsippany, NJ); Precision BioLogic Inc. (Halifax, Nova Scotia, Canada); Siemens Healthcare Inc. (Deerfield, IL); TCoag (Parsippany, NJ); Instrumentation Laboratories (Bedford, MA); and Sekisui Diagnostics (Pfungstadt, Germany).

Methods For all assays, we employed the STA-R Evolution automated coagulometer, adhering to manufacturers' instructions. LA-positive and LA-negative plasma controls were purchased from Diagnostica Stago and pooled normal plasma (PNP) was purchased from Precision BioLogic. We computed the mean of the reference interval (MRI) and action limits for all kits using LA-negative aliquots from locally sourced normal subjects (n = 42). We then assayed locally sourced LA-positive plasmas (n = 43) and using analysis of variance compared uncorrected screen/confirm ratios and screen/confirm ratios that were normalized using MRI and mean PNP results.

Results The grand mean action limit, MRI + 3 SD, derived from the local normal plasmas, was 1.2, confirming the manufacturers' recommended limits; however, limits must be locally computed. The all-sample p value was less than 0.001, indicating heterogeneity among ratios. When Sekisui ratios were excluded, the p value was 0.14, thus indicating that this method introduced the major difference among methods. Mean screen/confirm ratios computed from LA-positive specimens were 1.91 to 2.04 for reagent systems other than Sekisui, which instead yielded a mean ratio of 1.198, indicating that this method was relatively insensitive to LA. A negative bias was recorded by two lots from the Sekisui system for LA-positive specimens. Screen/confirm ratios from combined LA-positive and LA-negative samples generated a combined range of 1.59 to 1.67 for all reagents except Sekisui, which instead yielded 1.09. The within-run percent coefficient of variation (CV%) was less than 5.0% using all samples. Between-run CV% using Diagnostica Stago LA-positive and LA-negative controls was less than 5.5%.

Conclusions DRVVT screen/confirm ratios discriminate between LA-positive and LA-negative samples and generally provide acceptable reproducibility. Ratio results may vary among reagent–instrument combinations. In this study, normalization added little to the clinical result interpretation.

Keywords

dilute Russell viper venom time - lupus anticoagulant - antiphospholipid antibody - LA-sensitive partial thromboplastin time - mean of the reference interval - normalization

• References

• 1 Fritsma GA. Thrombosis risk testing. In: Rodak BF, Fritsma GA, Keohane EM, , eds. Hematology: Clinical Principles and Practices. 4th ed. St Louis, MO: Elsevier; 2012
• 2 Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II—Lupus anticoagulant. Semin Thromb Hemost 2012; 38 (4) 404-411
• 3 Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012; 38 (4) 375-384
• 4 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
• 5 Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011; 49 (3) 447-461
• 6 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68 (4) 869-874
• 7 Moore GW, Savidge GF, Smith MP. Improved detection of lupus anticoagulants by the dilute Russell's viper venom time. Blood Coagul Fibrinolysis 2000; 11 (8) 767-774
• 8 Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun 2000; 15 (2) 173-178
• 9 Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisløff F. The evaluation of clotting times in the laboratory detection of lupus anticoagulants. Thromb Res 2001; 104 (4) 275-282
• 10 Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol 2009; 83 (1) 1-16
• 11 Jennings I, Kitchen S, Kitchen DP, Woods TAL, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories?. J Thromb Haemost 2011; 9 (10) 2117-2119
• 12 Aboud MR, Roddie C, Ward CM, Coyle L. The laboratory diagnosis of lupus anticoagulant in patients on oral anticoagulation. Clin Lab Haematol 2006; 28 (2) 105-110
• 13 Schjetlein R, Sletnes KE, Wisløff F. A quantitative, semi-automated and computer-assisted test for lupus anticoagulant. Thromb Res 1993; 69 (2) 239-250